As public awareness rises, doctors are being called to bridge the knowledge gap, offer screening, and guide patients through complex and evolving risks.
Patients from the MeninGene study contributed serum samples over 5 years, revealing that autoimmune processes rarely drive long-term cognitive problems after bacterial meningitis.
A large UK study found no significant difference in treatment effectiveness between abatacept and adalimumab for rheumatoid arthritis, regardless of patients’ HLA-DRB1 genetic profiles.
A new study identified human pegivirus in the brains and blood of patients with Parkinson’s disease, revealing virus-linked immune and gene expression changes that varied by genetic background.
Tyzavan is the first FDA-approved vancomycin formulation available at room temperature that requires no compounding, thawing, or dilution, enabling faster treatment in time-critical infections like sepsis.
New research highlights strong associations between metabolic syndrome and several oral diseases—including periodontitis, caries, and peri-implantitis—calling for more longitudinal studies to explore causation and improve patient care.
GAMMAGARD LIQUID ERC is the first ready-to-use liquid immunoglobulin therapy with IgA ≤2 µg/mL for primary immunodeficiency in individuals aged 2 years and older.
Researchers identified segment-specific effects of immune cells on intestinal contractions, providing new angles for managing inflammatory bowel disease.